Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Migraine is a highly prevalent neurological disorder characterized by recurrent, often debilitating headaches accompanied by sensory disturbances such as nausea, photophobia, and phonophobia. As reported by global burden analyses covering 1990 to 2021, migraine prevalence increased by 58.15%, rising from 732.56 million to 1.16 billion cases worldwide, while incidence grew by 42.06%. According to migraine pipeline analysis by Expert Market Research, ongoing drug development spans small molecules, monoclonal antibodies, and novel preventive and acute therapies targeting CGRP pathways. The increasing disease burden, improved diagnosis rates, and strong focus on targeted mechanisms and long-acting treatments are expected to drive sustained pipeline expansion in the coming years.
-
Major companies involved in the migraine pipeline analysis include AbbVie, Pfizer, and others.
-
Leading drugs currently in the pipeline include Zavegepant, MEDI0618, and others.
-
The migraine market is driven by the rising global prevalence of migraine disorders, increasing diagnosis rates, and the growing adoption of targeted therapies such as CGRP inhibitors and novel small-molecule treatments.
Report Coverage
The Migraine Pipeline Analysis Report by Expert Market Research gives comprehensive insights into migraine therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for migraine. The migraine report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The migraine pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with migraine treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to migraine.
Read more about this report - Request a Free Sample
Migraine Pipeline Outlook
Migraine is a common and disabling neurological disorder characterized by recurrent headache attacks often accompanied by nausea, photophobia, and phonophobia, with symptoms frequently beginning in childhood or adolescence and persisting into adulthood. The condition poses a significant global health burden due to its high prevalence, recurrent nature, and impact on daily functioning and productivity.
Migraine treatment focuses on acute relief and long-term prevention through targeted therapies acting on key pain pathways such as calcitonin gene-related peptide (CGRP). A major milestone was the US FDA approval of rimegepant in February 2020 for acute migraine treatment, followed by an expanded approval in May 2021 for preventive therapy. Continued clinical development of CGRP antagonists, including pediatric and adolescent studies of rimegepant and zavegepant, along with exploration of novel targets, is expected to strengthen the migraine pipeline and improve therapeutic outcomes in the coming years.
Migraine Epidemiology
The migraine pipeline continues to progress as expanding epidemiological evidence informs research prioritization and regulatory planning. According to the Global Burden of Disease (GBD) 2021 study by the Institute for Health Metrics and Evaluation (IHME), migraine affected approximately 1.16 billion people globally in 2021, representing an age-standardized prevalence of about 14.7%, underscoring its substantial public health burden.
In the United States, data from the Centers for Disease Control and Prevention (CDC) indicate that around 15.9% of adults, equivalent to nearly 39 million individuals, experience migraine, with a higher prevalence among women. Similarly, government-aligned GBD estimates used by European health authorities suggest a prevalence of 14–18% across Europe, affecting approximately 95–110 million people. Collectively, these epidemiological insights highlight the widespread and growing burden of migraines, supporting sustained investment in targeted therapies, pediatric development programs, and innovative clinical pipelines aimed at improving long-term disease management.
Migraine – Pipeline Therapeutic Assessment
This section of the report covers the analysis of migraine drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The migraine pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Oligonucleotide
- Peptide
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Migraine Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with 47%, covers a major share of the total migraine clinical trials. It is followed by phase IV at 26% and other phases. This distribution reflects a mature and advancing pipeline, with a strong emphasis on late-stage development and post-approval evaluation aimed at optimizing therapeutic outcomes and expanding clinical use.
Migraine Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the migraine pipeline analysis include small molecules, peptides, and oligonucleotides. The migraine report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Migraine. For example, rimegepant is a small-molecule CGRP receptor antagonist currently evaluated across multiple clinical phases for the acute and preventive treatment of migraine, highlighting the strong dominance of small molecules within the migraine therapeutic pipeline.
Migraine Clinical Trials – Key Players
The EMR report for the migraine pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed migraine therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in migraine clinical trials:
- AbbVie
- Pfizer
- Amgen
- Eli Lilly and Company
- H. Lundbeck A/S
- Ipsen
- Merz Therapeutics GmbH
- Biohaven Pharmaceuticals
- Axsome Therapeutics
- Teva Pharmaceuticals
Migraine – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for migraine. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of migraine drug candidates.
Drug: Rimegepant
Rimegepant is being evaluated in a Phase 3 interventional clinical trial sponsored by Pfizer to assess its safety and efficacy in adolescents aged 12–17 years with frequent migraine. This randomized, placebo-controlled study aims to determine whether rimegepant can reduce migraine frequency and improve clinical outcomes, while also assessing tolerability and safety. Rimegepant is a small-molecule CGRP receptor antagonist that works by blocking calcitonin gene-related peptide signaling, a key pathway involved in migraine pathophysiology, thereby helping to prevent and relieve migraine attacks. The study is currently recruiting, with an estimated primary completion in October 2026 and final study completion in December 2027.
Drug: MEDI0618
MEDI0618 is being evaluated in a Phase 2 interventional clinical trial sponsored by AbbVie and AstraZeneca to assess its safety and efficacy compared to placebo in adult participants with episodic migraine. The study aims to determine whether MEDI0618 can reduce migraine headache days and improve clinical outcomes while evaluating tolerability and safety. MEDI0618 is a fully humanized monoclonal antibody that specifically inhibits protease-activated receptor-2 (PAR2), a G-protein-coupled receptor expressed in meningeal neurons, fibroblasts, and mast cells. By blocking PAR2 signaling, MEDI0618 may prevent inflammatory and pain-related pathways involved in migraine and reduce migraine-like responses, including CGRP-dependent and CGRP-independent mechanisms, as demonstrated in preclinical models.
Drug: Zavegepant
Zavegepant (PF-07930207) is being evaluated in a Phase 1 interventional clinical trial sponsored by Pfizer to study its safety, tolerability, and pharmacokinetics in children with a history of migraine. This recruiting study focuses on the acute treatment of migraine and aims to understand how pediatric patients respond to zavegepant following administration, supporting age-appropriate dosing and safety profiling. Zavegepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist administered as a nasal spray, designed to rapidly block CGRP signaling, a central mediator of migraine pain and neurogenic inflammation, thereby providing fast relief from acute migraine attacks. The study is expected to be completed in August 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Migraine Pipeline Insight Report
- Which companies/institutions are leading migraine drug development?
- Which company is leading migraine pipeline development activities?
- What is the current migraine commercial assessment?
- What are the opportunities and challenges present in the migraine pipeline landscape?
- What is the efficacy and safety profile of migraine pipeline drugs?
- Which company is conducting major trials for migraine drugs?
- Which companies/institutions are involved in migraine collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in migraine?
Reasons To Buy This Report
The Migraine Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for migraine. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into migraine collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share